Drugs / CB307
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05836623 | Dec 2022 → Jan 2024 | — | Crescendo Biologics Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04839991 | Jun 2021 → Jul 2024 | — | Crescendo Biologics Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2024-09-14 | Crescendo Biologics Ltd. | Results Crescendo Biologics announces clinical biodistribution data of Humabody® bispecific CB307 at ESMO 2024 crescendobiologics.com ↗
The results show that CB307 successfully localised to the tumour with negligible uptake in PSMA-positive normal tissues, lymph nodes, bone marrow and salivary glands, aligning with the intended biodistribution profile. |
| 2024-04-10 | Crescendo Biologics Ltd. | Results Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 crescendobiologics.com ↗
Preclinical data demonstrate strong rationale for ongoing Phase 1b POTENTIA trial investigating conditional CD137 (4-1BB) agonist CB307 as monotherapy and in combination with pembrolizumab in patients with prostate cancer |
| 2024-02-09 | Crescendo Biologics Ltd. | Results Crescendo Biologics announces publication in Neoplasia of preclinical tumour penetration data supporting CB307 crescendobiologics.com ↗
The data generated by the team at the University of Michigan further validates CB307’s potential in a clinical setting. |
All press releases naming this drug 8 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB307 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04839991 ↗ |
| Modality | Other / unclassified | “a trispecific Humabody® T-cell enhancer” NCT04839991 ↗ |
| Route | Intravenous | “CB307 IV infused every 7 days” NCT04839991 ↗ |